Indication: For the maintenance treatment of asthma as prophylactic therapy and for patients requiring oral corticosteroid therapy for asthma
Pharmacology: Fluticasone Propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma.
Mechanism Of Action: Binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve release of cytosolic phospholipase A2 which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Absorption: The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier.
Interactions:
DrugBank: Interactions for Fluticasone Propionate
Drug Interactions for Fluticasone Propionate:
No Information Provided.
Chemical IUPAC Name: [6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]propanoate
Chemical Formula: C25H31F3O5S
Half Life: 10 hours
Drug Type: Approved Drug
# Accession No: APRD00065
CAS Registry Number: 80474-14-2
Fluticasone Propionate News (When available)
Treating inflamed nasal area is routineDec 18, 2005 Daytona Beach News-Journal, ...most effective medication available to control sneezing, itching, a runny nose and nasal congestion are corticosteroid nasal sprays such as Flonase, Nasacort AQ ...
Opelousas Health Care ProblemDec 19, 2005 KLFY, When asked what he did, Aymond says he just didn't get it filled. Aymond's concern goes far beyond a prescription for Flonase. Captain ...
Inhaled Steroid Controls Asthma Better Than Oral AgentJan 12, 2006 CNN Their study compared the inhaled corticosteroid Flovent (fluticasone) with the oral leukotriene receptor antagonist Singulair (montelukast) for asthma control ...
SIXTH ANNUAL REPORT: FUTURE BLOCKBUSTERSDec 30, 2005 Med Ad News (subscription), ...with fluticasone. Fluticasone is the main ingredient in GlaxoSmithKline’s marketed blockbuster respiratory brand Flovent. A dosage ...
Health NewsDec 20, 2005 Hampton Union, ...qualify. If you take Flovent, Combivent, Proventil, Advair, Pulmicort, Serevent, Atrovent or any other inhaler, the program may help. ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
